Bellicum Pharmaceuticals (BLCM) BPX-501 Moving Faster Than Many Realize, Piper Jaffray Says

Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and $45 price target on Bellicum Pharmaceuticals (NASDAQ: BLCM) saying BPX-501 is moving faster than many realize.

Schimmer commented, "As we pass the halfway mark of 2015, we are refreshing our outlooks for our coverage universe. For BLCM, shares have drifted considerably following the company's lockup expiry, masking the tremendous progress BPX-501 is making in the clinic. Over 40 patients have been treated with this product as an augment to patients undergoing allogenic hematopoetic stem cell transplant with T-cell depletion. These regimens are used for congenital diseases or cancer in settings where an ideal match is not available but transplant is still required. Given the pace of early enrollment, BLCM may be much closer to assembling a registration dataset for BPX-501 than many realize. As well, the company's GoCAR and CIDeCAR platforms are advancing with potential important differentiation over earlier generation CAR-T products."

For an analyst ratings summary and ratings history on Bellicum Pharmaceuticals click here. For more ratings news on Bellicum Pharmaceuticals click here.

Shares of Bellicum Pharmaceuticals closed at $18.98 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• CIMC Enric Holdings Ltd. (3899:HK) (CIMEF) PT Lowered to HK$8.70 at HSBC
• BMO Capital Reiterates Outperform Rating on National Health Investors (NHI)